Phase I Multi-Center Study of Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Cervical cancer; Vulvovaginal cancer
- Focus Adverse reactions
- 08 May 2019 Planned End Date changed from 1 Oct 2020 to 31 Oct 2020.
- 08 May 2019 Planned primary completion date changed from 1 Oct 2019 to 31 Oct 2019.
- 31 Aug 2018 Biomarkers information updated